daily oral glp-1 receptor agonist orforglipron for adults with obesity Pill Approved by FDA Oral GLP-1 Receptor Agonist for

We compared GLP-1RAs with SGLT2 inhibitors and metformin and found that GLP-1RAs significantly reduced the incidence of major CVEs and mortality rate compared with metformin and second- or third-line glucose-lowering medications

During this stage, 300 articles were excluded due to irrelevance to the research question or failure to meet the inclusion criteria (22 clinical trials, 43 reviews or other unfitting literature, 112 wrong cell type, 49 wrong focus, 10 wrong drugs, 57 in vivo, 2 retractions, 3 no abstract and 2 not peer reviewed yet)

Hormonal Modulation: Decreased free testosterone and increased SHBG following treatment reflect reduced hyperandrogenism

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease